Skip to main content
. 2013 Jul 2;11:162. doi: 10.1186/1479-5876-11-162

Table 4.

Univariate and multivariate analyses of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) in relation to clinical parameters

Univariate survival analysis
 
OS
DFS
PFS
Variables N HR 95% CI p N HR 95% CI p N HR 95% CI p
LipB mRNA RQ
 
 
 
 
 
 
 
 
 
 
 
 
Low vs high tertile
92
1.6
0.7-3.3
0.220
64
2.5
1.1-5.6
0.020
88
2.2
1.1-4.3
0.030
LipB IHC
 
 
 
 
 
 
 
 
 
 
 
 
Continuous
92
1.4
0.6-3.3
0.400
67
0.99
0.3-2.4
0.980
91
1.3
0.6-2.8
0.499
LipB IHC
 
 
 
 
 
 
 
 
 
 
 
 
Categoric
 
 
 
 
 
 
 
 
 
 
 
 
IHC = 2 vs IHC ≤ 1
92
0.8
0.4-1.6
0.604
67
0.81
0.4-1.6
0.552
91
0.9
0.5-1.7
0.892
IHC = 3 vs IHC ≤ 1
 
1.7
0.7-3.7
0.183
 
1.15
0.4-2.9
0.764
 
1.4
0.6-3.1
0.353
Age (years)
 
 
 
 
 
 
 
 
 
 
 
 
>60 vs ≤60
92
2.0
1.1-3.7
0.017
67
1.15
0.6-2.1
0.660
91
1.85
1.1-3.2
0.026
FIGO stage
 
 
 
 
 
 
 
 
 
 
 
 
III-IV vs I-II
92
8.1
2.5-26.2
<0.01
67
6.6
2.5-17.1
<0.01
91
7.8
2.8-21.7
<0.01
Residual tumor (cm)
 
 
 
 
 
 
 
 
 
 
 
 
RT > 0 vs RT = 0
92
3.7
1.8-7.8
<0.01
67
2.4
1.2-4.6
0.010
91
3.4
1.7-6.5
<0.01
Presence of ascites
 
 
 
 
 
 
 
 
 
 
 
 
Yes vs no
92
2.6
1.4-5.1
0.003
67
2.8
1.4-5.4
0.002
91
2.6
1.4-4.7
<0.01
Lymph node involvement
 
 
 
 
 
 
 
 
 
 
 
 
Positive vs negative
73
1.9
0.9-4.0
0.04
58
3.4
1.7-6.7
0.001
73
2.8
1.4-5.2
0.002
Multivariate survival analysis
Variables
OS
DFS
PFS
N
HR
95% CI
p
N
HR
95% CI
p
N
HR
95% CI
p
LipB mRNA RQ
 
 
 
 
 
 
 
 
 
 
 
 
Low vs high tertile
92
1.8
0.9-3.9
0.103
64
3.9
1.7-9.1
0.001
88
2.8
1.4-5.8
0.004
FIGO stage
 
 
 
 
 
 
 
 
 
 
 
 
III-IV vs I-II
92
5.1
1.2-20.5
0.022
67
13.7
4.3-43.2
<0.01
91
5.8
1.7-19.4
0.004
Residual tumor (cm)
 
 
 
 
 
 
 
 
 
 
 
 
RT > 0 vs RT = 0
92
1.1
0.4-2.9
0.799
67
4.9
0.07-0.57
0.003
91
1.02
0.4-2.3
0.964
Presence of ascites
 
 
 
 
 
 
 
 
 
 
 
 
Yes vs no 92 1.6 0.8-3.4 0.180 67 3.3 1.3-8.3 0.009 91 1.8 0.9-3.6 0.095